In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. Wall Street had a big reaction to H5N1 bird flu news yesterday. Was it warranted? We’ll discuss that today.

The need-to-know this morning

• Bicycle Therapeutics raised $555 million in a PIPE transaction with a syndicate of health care investors.
• Adam Feuerstein’s take on Cytokinetics’ financing: CEO Robert Blum is once again on his Worst CEO shortlist.

U.S. in talks with mRNA vaccine makers on bird flu

While there is no indication the U.S. government plans to order mass production of vaccine for H5N1 bird flu at this point, Dawn O’Connell, assistant secretary for preparedness and response at HHS, said yesterday that some additional steps are being taken.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In